

ASX ANNOUNCEMENT

ASX: 1AI | 2 April 2026

TGA Accepts Initial Registration Dossier for Evaluation

Algorae Pharmaceuticals Ltd (ASX: 1AI) ("Algorae" or "the Company") is pleased to announce that the Therapeutic Goods Administration ("TGA") has accepted the Company's initial registration dossier for evaluation. Acceptance confirms the application has met the TGA's preliminary assessment requirements and will now progress through the formal evaluation process. This marks a significant execution milestone in the Company's pathway to product commercialisation in the Australian market.

The Company notes that application acceptance represents an early step in the regulatory review process and does not indicate the outcome of the evaluation.

The Company will provide regular aggregated updates on TGA applications and related progress.

Commercial Context

Algorae's commercial division, AlgoraeRx, has executed Licence and Supply Agreements with **Sakar Healthcare Limited** and **Cadila Pharmaceuticals Limited**, covering an initial portfolio of seven (7) generic medicines for the Australian and New Zealand markets. The product subject to this application submission is the first of those products to enter the TGA registration process. TGA registration, if achieved, will enable commercial supply under the Algorae Pharmaceuticals brand.

Pipeline

This is the first of multiple planned TGA registration submissions. The Company is progressing further applications across its medicine portfolio alongside a range of commercial and licensing initiatives.

Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd

END.

Corporate and Media Enquiries

Mr David Hainsworth

Executive Chairman

E: inquiries@algoraepharma.com

About Algorae Pharmaceuticals

Algorae Pharmaceuticals Ltd (ASX: 1AI) is an AI-enabled pharmaceutical company with a dual focus on drug-combination discovery and pharmaceutical commercialisation. The Company's proprietary AI platform, AlgoraeOS, applies artificial intelligence to identify synergistic drug combinations and inform preclinical experimental design. In parallel, Algorae operates a commercialisation business, AlgoraeRx, which sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through manufacturing partners and established distribution channels. Algorae collaborates with research institutions and industry partners to translate AI-predicted therapies and expand patient access to high-quality medicines. For more information visit www.algoraepharma.com or follow @algoraepharma on X or LinkedIn.

Forward-looking Statements

This document may contain certain forward-looking statements, relating to Algorae's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Algorae is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.